Delcath Systems (NASDAQ:DCTH) Stock Price Expected to Rise, HC Wainwright Analyst Says

Delcath Systems (NASDAQ:DCTH) had its target price upped by equities research analysts at HC Wainwright from $22.00 to $24.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 84.62% from the company’s current price. HC Wainwright also issued estimates for Delcath Systems’ FY2029 earnings at $1.58 EPS.

Separately, Craig Hallum boosted their target price on Delcath Systems from $18.00 to $21.00 and gave the company a “buy” rating in a research report on Friday, January 17th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, Delcath Systems presently has an average rating of “Moderate Buy” and a consensus price target of $22.75.

Delcath Systems Stock Performance

Shares of DCTH opened at $13.00 on Friday. The firm has a market cap of $415.66 million, a PE ratio of -9.63 and a beta of 0.82. Delcath Systems has a 52-week low of $3.70 and a 52-week high of $16.97. The business’s 50 day moving average price is $14.42 and its two-hundred day moving average price is $11.69.

Delcath Systems (NASDAQ:DCTH) last released its earnings results on Thursday, March 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). The company had revenue of $15.10 million for the quarter, compared to analyst estimates of $14.96 million. Delcath Systems had a negative net margin of 150.70% and a negative return on equity of 338.16%. During the same quarter in the previous year, the firm earned ($0.48) EPS. Research analysts predict that Delcath Systems will post -0.79 EPS for the current fiscal year.

Institutional Investors Weigh In On Delcath Systems

Several hedge funds and other institutional investors have recently made changes to their positions in DCTH. Principal Financial Group Inc. bought a new position in Delcath Systems in the 3rd quarter valued at about $808,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Delcath Systems in the third quarter valued at approximately $102,000. Polar Asset Management Partners Inc. purchased a new position in shares of Delcath Systems during the third quarter valued at approximately $1,594,000. State Street Corp raised its position in Delcath Systems by 12.4% in the 3rd quarter. State Street Corp now owns 85,457 shares of the company’s stock valued at $772,000 after buying an additional 9,400 shares during the last quarter. Finally, Jane Street Group LLC bought a new position in Delcath Systems during the 3rd quarter valued at $110,000. 61.12% of the stock is owned by institutional investors.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.